Physician profile
Peter R Shulman
NPI 1073692927
$2,422.88
in general payments reported to CMS, 2019-2025
24 companies · $750 in 2025
The $750 reported for 2025 was more than what 95% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $215 · 2021: $373 · 2022: $150 · 2023: $267 · 2024: $333 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $349.07 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $245.46 | 2019-2025 | |
| Corium, LLC | $225.68 | 2021-2025 | Azstarys |
| Kaleo, INC. | $216.53 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $184.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $172.48 | 2019-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $160.73 | 2020-2021 | |
| Cranial Technologies, INC | $155.53 | 2019-2025 | Doc Band |
| Biofire Diagnostics, LLC | $93.03 | 2019-2020 | |
| Seqirus USA INC | $85.19 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $73.05 | 2025 | |
| Phadia US INC. | $61.84 | 2023-2025 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $53.65 | 2025 | Neffy |
| Alk-Abello, INC | $50.93 | 2025 | Neffy |
| Novo Nordisk INC | $49.62 | 2024 | Wegovy, Saxenda |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $39.35 | 2023-2025 | |
| Noven Therapeutics, LLC | $37.37 | 2024-2025 | Xelstrym |
| Verrica Pharmaceuticals INC. | $36.83 | 2023-2024 | Ycanth |
| Cognoa, INC. | $26.10 | 2021 | |
| Tris Pharma INC | $24.75 | 2025 | Dyanavel Xr |
| Shire North American Group INC | $23.81 | 2019 | |
| Horizon Therapeutics Plc | $20.60 | 2019 | |
| Genzyme Corporation | $19.55 | 2022 | |
| Advanced Respiratory, INC | $17.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Shulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.